Inclusion Criteria

●    Patients (any sex, age 22-80) with confirmed diagnosis of hepatocellular chronic liver disease (CLD) including NAFLD (NAFL/NASH), Chronic HBV (presence of detectable HbsAg for more than 6 months) and/or HCV and have previously undergone fibrosis staging either by liver biopsy (within 2-8 weeks prior to OnX scan) or elastography (transient elastography, shear wave elastography, MRE). 
●    Patients (any sex, age 22-80) with suspected hepatocellular chronic liver disease (CLD) including NAFLD (NAFL/NASH), Chronic HBV (presence of detectable HbsAg for more than 6 months) and/or HCV.
●    Ability to understand and willingness to sign a written informed consent document.
●    Patients must be fasting for 3 hours, prior to both the OnX scan and FibroScan® exam.

Exclusion Criteria

●    Age <22 or >80
●    Inability to consent
●    Active, documented jaundice, cholestasis or elevated total bilirubin levels 1.5 -2 x ULN (> 1.2 mg/dL or 20.5 µmol/L)
●    Documented or known ascites
●    Documented or known portal hypertension secondary to non-cirrhotic etiologies (Budd-Chiari syndrome, congestive heart failure, extrahepatic portal vein thrombosis)
●    History of solid organ transplant
●    Prior diagnosis of hepatocellular carcinoma, cholangiocarcinoma or metastatic carcinoma
●    BMI greater than 32 kg/m2Berger et al. (2019)* 
●    Individuals with acute abdominal conditions, ascites, local skin diseases and severe musculoskeletal disorders that would not allow comfortable ultrasound assessment of the liver
●    Pregnant or suspicion of pregnancy
●    Individuals with current ethanol abuse (alcohol consumption exceeding 2 standard drinks per day on average [1 standard drink = 12 grams of alcohol])
●    Individuals with implanted electrical devices such as pacemakers, internal defibrillators, cochlear implants and nerve stimulators
●    History of Primary Biliary Cholangitis / Primary Sclerosing Cholangitis
●    History of autoimmune hepatitis 
●    History of congestive heart failure
●    Acute viral hepatitis A infection 
●    Acute or Chronic Hepatitis B with ALT levels ≥2 X ULN (or >35 U/L for men or >25 U/L for women)1  
●    Previous HCV infection and unable to achieve SVR12 with previous antiviral treatment for HCV
●    Drug Induced Liver Injury
●    Liver disease related to other systemic etiologies, including human immunodeficiency virus (HIV) infection, Wilson’s disease, hemochromatosis, alpha-1 antitrypsin deficiency, amyloidosis.